Endothelial Activation and Stress Index Score as a Prognostic Factor of Cytokine Release Syndrome in CAR-T Patients - A Retrospective Analysis of Multiple Myeloma and Large B-Cell Lymphoma Cohorts
- PMID: 39277881
- DOI: 10.2478/aite-2024-0018
Endothelial Activation and Stress Index Score as a Prognostic Factor of Cytokine Release Syndrome in CAR-T Patients - A Retrospective Analysis of Multiple Myeloma and Large B-Cell Lymphoma Cohorts
Abstract
Endothelial Activation and Stress Index (EASIX) has been proposed as a prognostic factor of adverse events or survival in hematological malignancies. Endothelial dysfunction has been associated with complications following stem cell transplantation and chimeric antigen receptor (CAR)-T therapy. This retrospective cohort study evaluated the utility of the EASIX score as a prognostic factor of cytokine release syndrome (CRS) in multiple myeloma/light-chain amyloidosis (MM/AL amyloidosis; N = 69) and large B-cell lymphoma (LBCL) cohorts (N = 65). Occurrence of CRS grade ≥3 was the primary endpoint. For both cohorts, the EASIX and simplified EASIX (s-EASIX) scores were calculated at four different time points before CAR-T infusion to assess its prognostic value. In the MM/AL amyloidosis cohort, neither EASIX nor s-EASIX scores calculated at any time point were associated with the occurrence of CRS grade ≥3. In the LBCL cohort, EASIX and s-EASIX scores measured before lymphodepletion (EASIX-pre and s-EASIX-pre) showed a significant relationship with CRS grade ≥3 (odds ratio [OR] = 1.06 and OR = 1.05, respectively). The cutoff value of 1.835 for EASIX-pre was associated with 4.59-fold increased OR of CRS grade ≥3 (95% confidence interval [CI]: 1.13-21.84), whereas s-EASIX-pre cutoff equaled 2.134 and was associated with 4.13-fold increased OR of CRS grade ≥3 (95% CI: 1.01-17.93). However, after internal validation with bootstrapping, the significance was lost both for the EASIX-pre and s-EASIX-pre cutoff. The presented findings indicate that the EASIX scores fail to predict CRS in MM/amyloidosis CAR-T patients, whereas they can be implemented as CRS grade ≥3 predictors in LBCL CAR-T patients.
Keywords: CAR-T; Cytokine release syndrome; Endothelium; Lymphoma; Myeloma.
© 2024 Jaromir Tomasik et al., published by Sciendo.
References
-
- Almici C, Skert C, Verardi R et al (2014) Changes in circulating endothelial cells count could become a valuable tool in the diagnostic definition of acute graft-versus-host disease. Transplantation 98:706–712. https://doi.org/10.1097/tp.0000000000000385
-
- Asherie N, Kfir-Erenfeld S, Avni B et al (2023) Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial. Haematologica 108:1827–1839. https://doi.org/10.3324/haematol.2022.281628
-
- Biedermann BC, Sahner S, Gregor M et al (2002) Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 359:2078–2083. https://doi.org/10.1016/s0140-6736(02)08907-9
-
- Cordes S, Mokhtari Z, Bartosova M et al (2021) Endothelial damage and dysfunction in acute graft-versus-host disease. Haematologica 106:2147–2160. https://doi.org/10.3324/haematol.2020.253716
-
- Eelen G, de Zeeuw P, Treps L et al (2018) Endothelial cell metabolism. Physiol Rev 98:3–58. https://doi.org/10.1152/physrev.00001.2017
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical